Skip to main content

Advertisement

SpringerLink
Log in

Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Acetylcholine is a modulatory central nervous system (CNS) neurotransmitter involved in diverse brain processes. Historically, drugs that increase CNS cholinergic transmission have been investigated primarily for relieving cognitive symptoms in Alzheimer’s disease (AD). Emerging from these efforts are recent findings that several cholinesterase-inhibitor agents also have a beneficial effect on selected noncognitive symptoms in AD, such as apathy, psychosis, and purposeless motor behaviors. The broad psychotropic effects of cholinergic agents observed in AD and other degenerative conditions highlight potential symptom-based therapeutic indications for these drugs across a variety of neurologic disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mesulam M-M: Structure and function of cholinergic pathways in the cerebral cortex, limbic system, basal ganglia, and thalamus of the human brain. In In Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York: Raven; 1995:135–146.

    Google Scholar 

  2. Geula C: Abnormalities of neural circuitry in Alzheimer’s disease: hippocampus and cortical cholinergic innervation. Neurology 1998, 51(suppl 1):S18–29.

    PubMed  CAS  Google Scholar 

  3. Ehlert FJ, Roeske WR, Yamamura HI: Molecular biology, pharmacology, and brain distribution of subtypes of the muscarinic receptor. In In Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York: Raven; 1995:111–124.

    Google Scholar 

  4. Arneric SP, Sullivan JP, Williams M: Neuronal nicotinic acetylcholine receptors: novel targets for central nervous system therapeutics. In In Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York: Raven; 1995:995–110.

    Google Scholar 

  5. Newhouse PA, Potter A, Levin ED, et al.: Nicotinic system involvement in Alzheimer’s and Parkinson’s diseases. Drugs Aging 1997, 11:206–228.

    PubMed  CAS  Google Scholar 

  6. Francis PT, Palmer AM, Snape M, Wilcock GK: The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999, 66:137–147. A comprehensive summary and update to the cholinergic hypothesis. This review discusses the role of cholinergic deficits in the broader context of other pathophysiologic lesions in AD, particularly in relation to glutamate neurotransmission. A thoughtful set of clinical practice guidelines for using AChE-I agents is included.

    PubMed  CAS  Google Scholar 

  7. Davis KL, Mohs RC, Marin D, et al.: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999, 281:1401–1406.

    Article  PubMed  CAS  Google Scholar 

  8. Procter AW, Lowe SL, Palmer AM, et al.: Topographical distribution of neurochemical changes in Alzheimer’s disease. J Neurol Sci 1988; 84:125–140.

    Article  PubMed  CAS  Google Scholar 

  9. Cutler NR, Sramek JJ: Muscarinic M1-receptor agonists: potential in the treatment of Alzheimer’s disease. CNS Drugs 1995, 3:467–481.

    CAS  Google Scholar 

  10. Cummings JL: Cholinesterase-inhibitors: a new class of psychotropic compounds. Am J Psychiatry 1999, in press. A state-of-the-art review of AChE-I studies conducted to date that highlights the principal psychotropic actions of these drugs and proposes new directions of investigation. The author systematically reviews and extends the rationale for viewing AChE-I agents as an emerging drug class with a novel spectrum of psychotropic properties.

  11. Sunderland T, Molchan SE, Little JT, et al.: Pharmacologic challenges in Alzheimer’s disease and normal controls: cognitive modeling in humans. Alz Dis Assoc Disord 1997, 11:S23–26.

    Google Scholar 

  12. Sarter M, Bruno J: Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Rev 1997, 23:28–46.

    Article  PubMed  CAS  Google Scholar 

  13. Lawrence AD, Sahakian BJ: The cognitive psychopharmacology of Alzheimer’s disease: focus on cholinergic systems. Neurochem Res 1998, 23:787–794.

    Article  PubMed  CAS  Google Scholar 

  14. Perry E, Walker M, Grace J, Perry R: Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999, 22:273–280. This paper offers a provocative neurobiologic perspective on acetylcholine as a neurotransmitter correlate of conscious awareness. Evidence linking topographically specific cholinergic dysfunction to alterations in REM sleep, hallucinations, attentional disturbances, and anesthesia-induced changes in awareness and arousal is synthesized into a novel view that these phenomena represent protean manifestations of altered consciousness.

    Article  PubMed  CAS  Google Scholar 

  15. Palmer AM, DeKosky ST: Monoamine neurons in aging and Alzheimer’s disease. J Neural Transm Gen Sect 1993, 91:135–159.

    Article  PubMed  CAS  Google Scholar 

  16. Raskind MA, Peskind ER: Neurologic bases of noncognitive behavioral problems in Alzheimer’s disease. Alz Dis Assoc Disord 1994, 8(suppl 3):54–60.

    Google Scholar 

  17. Cummings JL, Kaufer DI: Neuropsychiatric aspects of Alzheimer’s disease: the cholinergic hypothesis revisited. Neurology 1996, 47:876–883.

    PubMed  CAS  Google Scholar 

  18. Cummings JL, Back C: The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease. Am J Geriatr Psychiatry 1998, 6:S64-S78.

    PubMed  CAS  Google Scholar 

  19. Kaufer DI: Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase-inhibitors on neuropsychiatric symptoms in Alzheimer’s disease. Dementia Geriatr Cogn Disord 1998, 9(suppl 2):8–14.

    Article  CAS  Google Scholar 

  20. Cummings JL, Gorman DG, Shapira J: Physostigmine ameliorates the delusions of Alzheimer’s disease. Biol Psychiatry 1993, 33:536–541.

    Article  PubMed  CAS  Google Scholar 

  21. Gorman DG, Read SR, Cummings JL: Cholinergic therapy of behavioral disturbances in Alzheimer’s disease. Neuropsychiatry Neuropsychol Behav Neurol 1993, 6:229–234.

    Google Scholar 

  22. Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308–2314.

    PubMed  CAS  Google Scholar 

  23. Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J Geriatr Psychiatr Neurol 1996, 9:1–6.

    CAS  Google Scholar 

  24. Kaufer DI, Cummings JL, Christine D: Differential neuropsychiatric symptom responses to tacrine in Alzheimer’s disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998, 10:55–63.

    PubMed  CAS  Google Scholar 

  25. Raskind MA, Sadowsky CH, Sigmund WR, et al.: Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer’s disease. Arch Neurol 1997, 54:836–840.

    PubMed  CAS  Google Scholar 

  26. Kaufer DI, Catt K, Pollock BG, et al.: Donepezil in Alzheimer’s disease: relative cognitive and neuropsychiatric responses and their relationship to caregiver distress. Neurology 1998, 50:A89.

    Article  Google Scholar 

  27. Kaufer DI, Cummings JL, Christine D, et al.: Assessing the impact of behavioral disturbances in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998, 46:210–215.

    PubMed  CAS  Google Scholar 

  28. Morris JC, Cyrus PA, Orazem J, et al.: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998, 1222–1230. The first large-scale placebo-controlled study of AD to document the efficacy of an AChE-I drug on a global and specific measures of behavioral disturbances in patients with AD using the NPI. This study confirms similar findings observed with other AChE-I agents in small, uncontrolled studies, suggesting a general psychotropic action for this drug class.

  29. McKeith IG, Galasko D, Kosaka K, et al.: Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report on the consortium on DLB international workshop. Neurology 1996, 47:1113–1124.

    PubMed  CAS  Google Scholar 

  30. Shea C, MacKnight C, Rockwood K: Donepezil for treatment of Dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatrics 1998, 3:229–238.

    Article  Google Scholar 

  31. Kaufer DI, Catt K, Lopez O, et al.: Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 1998, 51:1512.

    PubMed  CAS  Google Scholar 

  32. Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatr 1996, 61:324–326.

    Article  PubMed  CAS  Google Scholar 

  33. Mendez MF, Younesi FL, Perryman KM: Use of donpezil for vascular dementia: preliminary clinical experience. J Neuropsychiatr Clin Neurosci 1999, 11:268–270.

    CAS  Google Scholar 

  34. Kuhl DE, Koeppe RA, Minoshima S, et al.: In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. Neurology 1999, 52:691–699. An exemplary study illustrating the development and validation of in vivo neurotransmitter ligand-binding tracers used in PET functional imaging. The authors discuss how such techniques may be used to investigate cholinergic mechanisms underlying therapeutic response to AChE-I agents. An accompanying commentary emphasizes the potential of such methods for investigating cholinergic substrates of behavior.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dementia Treatment Program, University of Pittsburgh School of Medicine, 4W ADRC, UPMC Montefiore, 200 Lothrop Street, 15213, Pittsburgh, PA, USA

    Daniel I. Kaufer MD

  2. University of Pittsburgh Alzheimer’s Disease Research Center, 4W ADRC, UPMC Montefiore, 200 Lothrop Street, 15213, Pittsburgh, PA, USA

    Daniel I. Kaufer MD

Authors
  1. Daniel I. Kaufer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaufer, D.I. Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders. Curr Psychiatry Rep 1, 78–84 (1999). https://doi.org/10.1007/s11920-999-0013-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-999-0013-1

Keywords

Search

Navigation